Novartis Stops Iscalimab Trial In Kidney Transplant Patients
- Novartis AG (NYSE: NVS) has halted a Phase 2 trial of CFZ533 (iscalimab) in kidney transplant patients.
- The decision follows interim data that showed iscalimab was not as good as tacrolimus-based treatment in preventing organ rejection.
- Iscalimab's study in liver transplant continues, and additional studies exploring the drug as a potential treatment in other conditions.
- Novartis is continuing to review the data from the CIRRUS-1 study. Once complete, the company will share the results with the broader scientific community.
- Price Action: NVS shares closed 0.54% lower at $92.15 on Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs kidney disease Phase 2 TrialBiotech News Health Care General
